Share on

North America Deep Brain Stimulation Market Research Report – Segmented By Product, Type, Application, End-Use and Country (The United States, Canada and Rest of North America) – Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2023 to 2028)

Published: March, 2023
ID: 11876
Pages: 100
Formats: report pdf report excel report power bi report ppt

North America Deep Brain Stimulation Market Size (2023 to 2028)

The size of the North American deep brain stimulation market is forecasted to be growing at a CAGR of 9.86% from 2023 to 2028.

The increasing incidences of neurological and motor disorders and the better success rate of minimally invasive (MI) surgeries are the main factors in the growth of the North American deep brain stimulation market. In addition to this, the growth of the market is also being boosted due to the growth of the geriatric population and increased awareness of the benefits of the DBS procedure, such as improvement in motor symptoms for a longer period of time and fewer side effects.

Factors such as rapidly increasing incidence of epilepsy, essential tremors, and increasing cases of Alzheimer's and Parkinson's are driving the growth of the market. New uses for DBS devices to treat Alzheimer's disease and tinnitus have created opportunities for new and existing players in the market. In addition, the prevalence of lifestyle-related diseases, such as obesity and hypertension-induced depression, is steadily increasing. DBS therapy is crucial in providing treatment to such grave diseases, leading to its rapid adoption around the world.

In addition, technological advances, such as the incorporation of robot-assisted implants and multi-target stimulation, and an increasing focus on research and development (R&D) activities to make it a completely non-invasive procedure in the future.

However, the risk of infection at the pacemaker site, the high cost associated with the surgery, and the delayed approval of the product by various government authorities are expected to hamper the market's growth.

Impact of COVID-19 on the North American deep brain stimulation market:

The whole world is fighting the new coronavirus. Governments in several countries have triggered the lockdown to thwart the spread of this deadly virus amid the pandemic. Such plans have disrupted the production and supply chain. As a result, deep brain stimulation device companies focus on improving efficiency and contain expenses under current COVID-19 market conditions.

The government in North America has recommended that elective medical procedures, including DBS surgery for PD, not be scheduled during the pandemic to prevent the further spread of the virus and overloaded health systems. However, reprogramming and delaying deep brain stimulation surgery for patients with advanced, drug-resistant PD may not be preferable for individual patients. Moreover, the restricted availability of medical resources, favoring some elective and urgent therapeutic procedures, may affect the market growth. Nevertheless, as control procedures, such as DBS, establish the progress of vaccination and the spread of the virus, the adoption rate may increase, which should provide opportunities for the market.

This research report on the North American deep brain stimulation market has been segmented and sub-segmented into the following categories:

By Product:

  • Single Channel
  • Dual-Channel

By Type:

  • Subthalamic DBS
  • Globus Pallidus DBS
  • Thalamic DBS
  • Pedunculopontine Nucleus DBS

By Application:

  • Pain Management
  • Epilepsy
  • Essential Tremor
  • Obsessive-Compulsive Disorder (OCD)
  • Depression
  • Dystonia
  • Parkinson’s Disease
  • Others

By End-Use:

  • Hospitals
  • Neurology Clinics
  • Ambulatory Surgical Centres
  • Research Centres

By Country:

  • The United States
  • Canada
  • Rest of North America

Geographically, the U.S. market is expected to dominate the North American DBS market with a higher market share than other regional markets and is expected to continue to dominate during the forecast period. This can be attributed to the increased incidence of Parkinson's disease among the population of this region and the presence of important market agents operating in the countries of this region. For example, according to the Depression and Bipolar Support Alliance, approximately 17.9 million adults in the United States have a major depressive disorder. Hence, many people suffering from these conditions and disorders are expected to drive market growth during the forecast period.

Canada is expected to experience significant growth during the forecast period 2022 to 2028 due to the prevalence of neurodegenerative disorders, the demand for effective and long-term solutions, improvements in the clinical development framework, and increased awareness of treatment options for neurological disorders. In addition, the high mortality rate, increased awareness of the massive burden of neurological diseases, improved health infrastructure, and increased health spending is positively affecting the deep brain stimulation market. Moreover, technological advancements in deep brain stimulation technologies provide a profitable opportunity in upcoming years.

KEY MARKET PARTICIPANTS:

Companies such as Medtronic, Aleva Neurotherapeutics, NeuroPace, Boston Scientific, Abbott (ST. JUDE MEDICAL), Beijing Pins Medical, Neuro Sigma, Functional Neuromodulation, Fisher Wallace, NeuroSigma Company, ANM Adaptive Neuromodulation GmbH, Renishaw plc, LivaNova PLC, SceneRay Corporation, Nevro Corp., and Neuronetics, Inc. are some of the noteworthy players in the North American deep brain stimulation market.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample